OXiGENE Reports Second Quarter 2012 Financial Results

August 9, 2012 |

1 min read

SOUTH SAN FRANCISCO, Calif., Aug. 8, 2012 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer, reported financial results for the quarter and six months ending June 30, 2012.

Earnings

MORE ON THIS TOPIC

Illustration of cardboard box filled with office supplies, a computer keyboard, lamp, and a potted plant

Layoff Tracker

4DMT Thins Early-Stage Workforce, Focuses on Late-Stage Activities

July 3, 2025

·

152 min read

·

BioSpace Editorial Staff

Podcast

CAR T Expands, M&A Ticks Up, Two Psychedelics Read Out, and the Supreme Court Rules on PrEP

July 2, 2025

·

1 min read

·

Heather McKenzie

A contemporary artistic collage depicting a hand holding pills, passing them to another hand. The concept of medication and treatment.

Collaboration

Argenx Makes $1.5B+ Play for UNP’s Macrocyclic Peptides Aimed at ‘Undruggable’ Targets

July 1, 2025

·

2 min read

·

Tristan Manalac

Contemporary art collage, female palms in the orange circle, a bag of money. Concept of business and finance.

Mergers & acquisitions

AbbVie Plunks Down $2.1B for Capstan and Its Novel CAR T Therapies

June 30, 2025

·

2 min read

·

Dan Samorodnitsky